Xlife Sciences AG: New project in the portfolio
Xlife Sciences AG invests in Laxxon Medical AG
Laxxon Medical AG
Laxxon Medical AG owns the exclusive global rights for development, production, and commercialization of an innovative new drug delivery system for the controlled release of pharmaceutical actives. This new process is based on a patented 3D printing process. The aim of Laxxon Medical AG is to grant sub-licenses of this new technology to selected companies in the pharmaceutical industry.
As part of the collaboration, Laxxon Medical AG will also support these companies with their own in-house expertise. They will help the selected companies find new opportunities to extend patent protection of existing products by protecting them from counterfeit products in the market. Laxxon Medical AG collaborates with internationally renowned research institutes and universities.
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
End of Media Release
Issuer: Xlife Sciences AG
Key word(s): Enterprise
15.10.2019 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.
|Company:||Xlife Sciences AG|
|Phone:||0041 44 385 84 60|
|Listed:||Regulated Unofficial Market in Munich|
|EQS News ID:||890019|
|End of News||DGAP Media|